Inhibitor Therapeutics (OTCMKTS:INTI) Issues Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) released its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Down 3.3 %

Inhibitor Therapeutics stock opened at $0.06 on Friday. Inhibitor Therapeutics has a 12-month low of $0.04 and a 12-month high of $0.14. The stock has a 50-day simple moving average of $0.06 and a 200 day simple moving average of $0.07. The stock has a market capitalization of $9.99 million, a price-to-earnings ratio of -5.80 and a beta of -0.55.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.